Last reviewed · How we verify

CJ Plasma Solution A Injection

Seoul National University Hospital · Phase 3 active Small molecule

CJ Plasma Solution A is a plasma-derived therapeutic that replenishes coagulation factors and other plasma proteins to support hemostasis and tissue repair.

CJ Plasma Solution A is a plasma-derived therapeutic that replenishes coagulation factors and other plasma proteins to support hemostasis and tissue repair. Used for Coagulopathy and hemostatic support (Phase 3 indication under investigation).

At a glance

Generic nameCJ Plasma Solution A Injection
SponsorSeoul National University Hospital
Drug classPlasma derivative
ModalitySmall molecule
Therapeutic areaHematology / Critical Care
PhasePhase 3

Mechanism of action

As a plasma-based injectable, this solution contains multiple coagulation factors, albumin, and immunoglobulins that work synergistically to restore hemostatic function and provide nutritional/immunological support. The exact composition and mechanism are proprietary to Seoul National University Hospital, but plasma solutions are typically used to correct coagulopathy, replace lost blood volume, and support wound healing or recovery in critical conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: